Unknown

Dataset Information

0

CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I.


ABSTRACT: CRISPR/Cas9 technology offers novel approaches for the development of new therapies for many unmet clinical needs, including a significant number of inherited monogenic diseases. However, in vivo correction of disease-causing genes is still inefficient, especially for those diseases without selective advantage for corrected cells. We reasoned that substrate reduction therapies (SRT) targeting non-essential enzymes could provide an attractive alternative. Here we evaluate the therapeutic efficacy of an in vivo CRISPR/Cas9-mediated SRT to treat primary hyperoxaluria type I (PH1), a rare inborn dysfunction in glyoxylate metabolism that results in excessive hepatic oxalate production causing end-stage renal disease. A single systemic administration of an AAV8-CRISPR/Cas9 vector targeting glycolate oxidase, prevents oxalate overproduction and kidney damage, with no signs of toxicity in Agxt1-/- mice. Our results reveal that CRISPR/Cas9-mediated SRT represents a promising therapeutic option for PH1 that can be potentially applied to other metabolic diseases caused by the accumulation of toxic metabolites.

SUBMITTER: Zabaleta N 

PROVIDER: S-EPMC6303323 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications


CRISPR/Cas9 technology offers novel approaches for the development of new therapies for many unmet clinical needs, including a significant number of inherited monogenic diseases. However, in vivo correction of disease-causing genes is still inefficient, especially for those diseases without selective advantage for corrected cells. We reasoned that substrate reduction therapies (SRT) targeting non-essential enzymes could provide an attractive alternative. Here we evaluate the therapeutic efficacy  ...[more]

Similar Datasets

| S-EPMC4886931 | biostudies-literature
| S-EPMC5280024 | biostudies-other
| S-SCDT-10_1038-S44321-023-00008-8 | biostudies-other
2023-11-10 | GSE245791 | GEO
| S-EPMC7014288 | biostudies-literature
| S-EPMC5037430 | biostudies-literature
| S-EPMC4730182 | biostudies-literature
| S-EPMC5309830 | biostudies-literature
| S-EPMC8633974 | biostudies-literature
| S-EPMC4886950 | biostudies-literature